Languages
Pages
Legal
Explore all categories to find your favorite topic
Geneva Branch EFFICACY ENDPOINTS IN ONCOLOGY – IS01 Bruxelles 13-16/10/2013 Angelo Tinazzi Cytel Inc., Wilmington Del. USA Succursale de Meyrin – Geneva – Switzerland…
Everything you need to know: Overview of Imaging Endpoints and FDA Guidelines for Use of Imaging in Oncology Clinical Trials The Median Technologies Innovation Team Contents…
$ % The Roles of Short Term Endpoints in Clinical Trial Planning and Design Christopher Jennison Department of Mathematical Sciences, University of Bath, UK http:people.bath.ac.ukmascj…
$ % The Roles of Short Term Endpoints in Clinical Trial Planning and Design Christopher Jennison Department of Mathematical Sciences, University of Bath, UK http:people.bath.ac.ukmascj…
FDA-AACR Immuno-Oncology Drug Development Workshop Transcript from October 14 2016 Section 1 of 45 00:00:00 - 00:10:04 NOTE: speaker names may be different in each section…
1. Comparison of effect sizes associated withsurrogate and final primary endpoints in randomised clinical trials Ciani O., Garside R., Pavey T., Stein K., Taylor R.S. 1 2.…
Zurich Open Repository and Archive University of Zurich Main Library Strickhofstrasse 39 CH-8057 Zurich wwwzorauzhch Year: 2018 Neoadjuvant rectal score as individual-level…
VARIABILE DI RISPOSTA • di tipo quantitativo – assume uno spettro continuo di valori e viene misurata in riferimento a una scala a intervalli costanti. • di tipo qualitativo…
Evaluating Causal Effect Predictiveness of Candidate Surrogate Endpoints Peter B. Gilbert1,∗ and Michael G. Hudgens2 1 Fred Hutchinson Cancer Research Center and Department…
Slide 1 CPCP Institute of Clinical Pharmacology The gap between biomarkers and surrogate endpoints Oncology Dr. Michael Zühlsdorf Bayer Healthcare AG Institute of Clinical…
Slide 1HIDING THE BODIES Slide 2 Wheezes Switching Endpoints Surrogate Outcomes 90%? NNT inappropriate LOCF Relative Risks Short term trials Miscoding Splitting Hazards Co-administration…
Biometrical Requirements in (Early) Benefit Assessments Ralf Bender Institute for Quality and Efficiency in Health Care (IQWiG) Cologne, Germany BBS 2012 Basel, 25.09.2012…
Slide 1Surrogate Endpoints: A Regulatory View Greg Campbell, Ph.D. Director, Division of Biostatistics Center for Devices and Radiological Health Food and Drug Administration…
Slide 1 Economic evaluation of outcomes: long term primary and surrogate endpoints Dr. Giampiero Favato presented at the University Program in Health Economics Ragusa, 26-28…
22-03-18 1 Jaap-Henk Hoepman * [email protected] // 8 www.cs.ru.nl/~jhh // 8 blog.xot.nl // @xotoxot Privacy & Identity Lab Radboud University Tilburg University University…
Shaping the Future of Drug Development Transparent machine learning Alind Gupta Real-World and Advanced Analytics Machine learning 4282020 Cytel Inc 2 • Algorithms that…
US Regulatory Perspective: Rare Tumors Amy Barone MD Medical Officer Division of Oncology Products 2 Office of Hematology and Oncology Products 1 2 Disclosures • No financial…
On Surrogate Endpoints in HIV Vaccine Efficacy Trials Steven Self, Peter Gilbert, Michael Hudgens FHCRC/UW FDA/Industry Statistics Workshop, Sept 18-19, 2003 “Statistics:…
Contents lists available at ScienceDirect Biochemical Pharmacology journal homepage: wwwelseviercomlocatebiochempharm Review Regulatory-accepted drug development tools are…
Slide 1 Microbiologic Surrogate Endpoints in Clinical Trials-IDSA FDA/IDSA/ISAP Workshop April 15, 2004 Sheldon L. Kaplan, MD Baylor College of Medicine Texas Children’s…